Comparison of the effectiveness of oral sildenafil versus oxygen administration as a test for feasibility of operation for patients with secondary pulmonary arterial hypertension

Pediatric Cardiology

Volumn 29, Issue 3, 2008, Pages 552-555

  Ajami, Gholam Hossein ^a,b   Borzoee, Mohammad ^a   Radvar, Mohammad ^a   Amoozgar, Hamid ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Congenital heart diseases; Hemodynamics; Oxygen; Secondary pulmonary arterial hypertension; Sildenafil

Indexed keywords

OXYGEN; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL;

ADOLESCENT; ANALYTIC METHOD; ARTICLE; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; CONGENITAL HEART DISEASE; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; HEART CATHETERIZATION; HEART HEMODYNAMICS; HEART SURGERY; HUMAN; INFANT; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; NASOGASTRIC TUBE; OXYGEN THERAPY; PULMONARY HYPERTENSION; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HEART CATHETERIZATION; HEART DEFECTS, CONGENITAL; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; INFANT; MALE; OXYGEN INHALATION THERAPY; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PULMONARY CIRCULATION; PURINES; SULFONES;

EID: 43549115248     PISSN: 01720643     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00246-007-9139-2     Document Type: Article

References (13)

1. Abrams D, Scbulze I, Magee A (2000) Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 84:1-4
2. Archer SL, Haung JM, Hampl V, et al. (1994) Nitric oxide and cGMP cause vasorelaxation by activation of charbdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc Natl Acad Sci USA 91:7583-7587
3. 2 for the evaluation of pulmonary vascular reactivity in patients with pulmonary arterial hypertention. Pediatr Cardiol 23:20-25
4. Barst RJ (2001) Clinical management of patients with pulmonary arterial hypertension. In: Allen HD, Gutgesell HP, Clarck E et al. (eds) Moss and Adam's heart disease in infants, children and adolescents, 6th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1347-1359
5. Erickson S, Reyes J, Bohn D, et al. (2002) Sildenafil in childhood and neonatal pulmonary arterial hypertension. J Am Coll Cardiol 39(Suppl):4029
6. Ghofrani H, Wiedmann R, Rose F, et al. (2002) Combination therapy with oral sildenafil and inhaled Iloprost for severe pulmonary hypertenstion. Ann Intern Med 136:515-522
7. Ghofrani HA, Voswinckel R, Reichenberger F, et al. (2004) Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension a randomized prospective study. J Am Coll Cardiol 44:1488-1496
8. Haworth SG (2001) Pathobiology of pulmonary hypertension in infants and children. Prog Pediatr Cardiol 12:249-269
9. Michelakis E, Farber H (2001) Current management of primary pulmonary hypertension. Drugs 61:1945-1956
10. Michelakis E, Tymchak W, Lien D, et al. (2002) Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 105:2398-2403
11. Wauthy P, Abdel Kafi S, Mooi WJ, et al. (2003) Inhaled nitric oxide versus prostacycline in chronic shunt induced pulmonary hypertension. J Thorac Cardiovas Surg 126:1434-1441
12. Weimann J, Ulrich R, Hormi J, et al. (2000) Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertention. Anesthediology 6:1702-1712
13. Zhao L, Mason NA, Morrel NW, et al. (2001) Sildenafil inhibits hypoxia induced pulmonary hypertension. Circulation 104:424-428